Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
- 11 December 2005
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 12 (1), 122-127
- https://doi.org/10.1038/nm1337
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Role ofVHLGene Mutation in Human CancerJournal of Clinical Oncology, 2004
- Regulation of HIF prolyl hydroxylases by hypoxia‐inducible factorsJournal of Cellular Biochemistry, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- A Novel Hypoxia-inducible Factor-independent Hypoxic Response Regulating Mammalian Target of Rapamycin and Its TargetsJournal of Biological Chemistry, 2003
- Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of RapamycinMolecular and Cellular Biology, 2002
- Addiction to Oncogenes--the Achilles Heal of CancerScience, 2002
- Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau proteinCancer Cell, 2002
- HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor ExpressionMolecular and Cellular Biology, 2001